Literature DB >> 26555176

SnapShot: Multiple Myeloma.

Esteban Braggio1, K Martin Kortüm1, A Keith Stewart1.   

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by a heterogeneous clinical presentation. Genetic abnormalities are not only key events in the origin and progression of the disease but are also useful tools for prognosis, risk stratification, and therapeutic decision making. Although still incurable, a revolution in the treatment of MM is currently ongoing, leading to a significant improvement of clinical outcome and survival. To view this SnapShot, open or download the PDF.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2015        PMID： 26555176      PMCID： PMC4864595          DOI： 10.1016/j.ccell.2015.10.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

Review 1.  Molecular pathogenesis and a consequent classification of multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

2.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Authors:  Joseph R Mikhael; David Dingli; Vivek Roy; Craig B Reeder; Francis K Buadi; Suzanne R Hayman; Angela Dispenzieri; Rafael Fonseca; Taimur Sher; Robert A Kyle; Yi Lin; Stephen J Russell; Shaji Kumar; P Leif Bergsagel; Steven R Zeldenrust; Nelson Leung; Matthew T Drake; Prashant Kapoor; Stephen M Ansell; Thomas E Witzig; John A Lust; Robert J Dalton; Morie A Gertz; A Keith Stewart; Keith Stewart; S Vincent Rajkumar; Asher Chanan-Khan; Martha Q Lacy
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

3.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

4.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

5.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 6.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

Review 7.  IMWG consensus on risk stratification in multiple myeloma.

Authors:  W J Chng; A Dispenzieri; C-S Chim; R Fonseca; H Goldschmidt; S Lentzsch; N Munshi; A Palumbo; J S Miguel; P Sonneveld; M Cavo; S Usmani; B G M Durie; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

8.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

9.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919
  9 in total
  13 in total

Review 1.  [Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview].

Authors:  K M Kortüm; H Einsele
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

Review 2.  Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2016-07-13       Impact factor: 2.490

3.  Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells.

Authors:  Garry P Nolan; Daniel H D Gray; Melissa E Ko; Charis E Teh; Jia-Nan Gong; David Segal; Tania Tan; Cassandra J Vandenberg; Pasquale L Fedele; Michael S Y Low; George Grigoriadis; Simon J Harrison; Andreas Strasser; Andrew W Roberts; David C S Huang
Journal:  Cell Death Differ       Date:  2020-01-27       Impact factor: 15.828

4.  A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies.

Authors:  Roberto De Luca; Paul Kachel; Klara Kropivsek; Berend Snijder; Markus G Manz; Dario Neri
Journal:  Protein Eng Des Sel       Date:  2018-05-01       Impact factor: 1.650

5.  Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

Authors:  Juan-Jose Lahuerta; Bruno Paiva; Maria-Belen Vidriales; Lourdes Cordón; Maria-Teresa Cedena; Noemi Puig; Joaquin Martinez-Lopez; Laura Rosiñol; Norma C Gutierrez; María-Luisa Martín-Ramos; Albert Oriol; Ana-Isabel Teruel; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Miguel T Hernandez; Luis Palomera; Rafael Martinez; Alejandro Martin; Adrian Alegre; Javier De la Rubia; Alberto Orfao; María-Victoria Mateos; Joan Blade; Jesus F San-Miguel
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544

6.  The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma

Authors:  Suchada Sommaluan; Budsaba Rerkamnuaychoke; Teeraya Pauwilai; Suporn Chancharunee; Preeyaporn Onsod; Pitichai Pornsarayuth; Takol Chareonsirisuthigul; Rachaneekorn Tammachote; Teerapong Siriboonpiputtana
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

7.  High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Authors:  A Miller; Y Asmann; L Cattaneo; E Braggio; J Keats; D Auclair; S Lonial; S J Russell; A K Stewart
Journal:  Blood Cancer J       Date:  2017-09-22       Impact factor: 11.037

Review 8.  NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.

Authors:  Chia-Hung Yen; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2018-11-07       Impact factor: 5.923

9.  Comment on: "Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma".

Authors:  Ilana Zalcberg Renault
Journal:  Rev Bras Hematol Hemoter       Date:  2016-03-18

10.  Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.

Authors:  Makoto Nakagawa; Shuhei Fujita; Takuo Katsumoto; Kazutsune Yamagata; Yoko Ogawara; Ayuna Hattori; Yuki Kagiyama; Daisuke Honma; Kazushi Araki; Tatsuya Inoue; Ayako Kato; Koichiro Inaki; Chisa Wada; Yoshimasa Ono; Masahide Yamamoto; Osamu Miura; Yasuharu Nakashima; Issay Kitabayashi
Journal:  Cancer Sci       Date:  2018-11-16       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.